SÖZ
ALTI
NEWS
Home
The day in news
This week
Archive
Crisis
About
EN
AZ
sözaltı
news
Finance
Finance
EN
AZ
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
marketwatch.com
08.09.2026 16:07
38 views
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Copy link
Save
Pick
Copy link
WhatsApp
Telegram
X
Reddit
Facebook
LinkedIn
Email
More
Image
Share image
Save
Copy link
Similar stories
2 outlets
See how this story developed, hour by hour
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
finance.yahoo.com
08.09.2026
Why Novartis’ Drug Trial Results Are Blowing Up Amgen Stock
barrons.com
08.09.2026
Related stories
Dolly Parton planned for her estate. The fight with her nephew shows why that matters.
marketwatch.com · 28.09
Spending $800 to see my family this Thanksgiving is a financial burden. How can I push for a cheaper flight?
marketwatch.com · 28.09
What a US diesel export ban could mean for you
bbc.co.uk · 28.09
The U.S. and China agree to $60 billion in tariff cuts on products like dolls and fireworks. Rare earths remain a sticking point.
marketwatch.com · 28.09
Aldi boss says some loyalty discounts 'dupe' customers
bbc.co.uk · 28.09
UK tries to stop Trump's diesel export ban
bbc.co.uk · 28.09
← Previous
IREN Surges 7% on Conditional ERCOT Status for 2GW Sweetwater Hub, Applied Digital Climbs 6%
Next →
EverBank and WaFd announce $3.9 billion reverse merger